|
Clinical
| |
H3K18Ac
|
(p)
|
SIRT2
|
(p)
|
P300
|
(p)
|
|---|
|
Extraprostatic Extension
|
No (46)
|
0.371(0.316–0.434)
| |
0.0152(0.010–0.019)
| |
0.135(0.125–0.150)
| |
| |
Yes (24)
|
0.375(0.308–0.414)
|
0.71
|
0.0132(0.011–0.017)
|
0.17
|
0.145(0.125–0.162)
|
0.09
|
|
Seminal Vesicle Invasion
|
No (54)
|
0.373(0.318–0.431)
| |
0.015(0.011–0.019)
| |
0.135(0.125–0.15)
| |
| |
Yes (17)
|
0.365(0.306–0.414)
|
0.41
|
0.011(0.010–0.016)
|
0.12
|
0.146(0.128–0.165)
|
0.03
|
|
Laterality
|
U/L (4)
|
0.380(0.323–0.410)
| |
0.010(0.0085–0.013)
| |
0.125(0.118–0.136)
| |
| |
B/L (67)
|
0.371(0.31–0.422)
|
0.92
|
0.015(0.011–0.018)
|
0.16
|
0.137(0.125–0.153)
|
0.20
|
|
Margins
|
No (44)
|
0.371(0.312–0.429)
| |
0.0157(0.011–0.019)
| |
0.139(0.126–0.158)
| |
| |
Yes (26)
|
0.373(0.306–0.414)
|
0.79
|
0.012(0.010–0.017)
|
0.07
|
0.132(0.125–0.147)
|
0.46
|
|
Clinical stage
|
II (42)
|
0.371(0.316–0.439)
| |
0.015(0.010–0.019)
| |
0.134(0.125–0.150)
| |
| |
III (12)
|
0.358(0.308–0.401)
| |
0.013(0.010–0.017)
| |
0.137(0.126–0.153)
| |
| |
IV (16)
|
0.396(0.311–0.414)
|
0.64
|
0.016(0.010–0.018)
|
0.58
|
0.146(0.126–0.163
|
0.13
|
|
PSA level (ng/ml)
|
0–5 (6)
|
0.343(0.296–0.456)
| |
0.011(0.009–0.015)
| |
0.136(0.124–0.146)
| |
| |
5–10 (35)
|
0.372(0.313–0.414)
| |
0.015(0.012–0.018)
| |
0.133(0.124–0.152)
| |
| |
>10 (12)
|
0.365(0.307–0.425)
|
0.96
|
0.011(0.010–0.019)
|
0.15
|
0.145(0.134–0.160)
|
0.51
|
|
Gleason score
|
|
(3 + 3, 3 + 4)
|
Low/Int (35)
|
0.371(0.321–0.441)
| |
0.015(0.012–0.019)
| |
0.128(0.121–0.142)
| |
|
(4 + 3,4 + 4, 4 + 5)
|
High (19)
|
0.345(0.298–0.412)
|
0.15
|
0.011(0.009–0.015)
|
0.02
|
0.134(0.124–0.152)
|
0.68
|
- Relative staining intensity of H3K18Ac, SIRT2 and P300 (mean, standard deviation expressed in 0D units) compared to clinicopathological correlates
